Molecular Partners Publishes Audited Financial Results and Annual Report 2016
Zurich-Schlieren, March 31, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published its audited Financial Results for 2016 and the company’s 2016 Annual Report.
The audited Financial Results for 2016 and the company’s 2016 Annual Report are available on the investors section of the company’ website.
Financial Calendar
| April 13, 2017 | Expected Publication of Invitation the Annual General Meeting 2017 |
| May 4, 2017 | Q1 2017 Management Statement |
| May 11, 2017 | Annual General Meeting |
| August 30, 2017 | Publication of 2017 Half-year Results |
| October 26, 2017 | Q3 2017 Management Statement |
http://investors.molecularpartners.com/financial-calendar-and-events/
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details please contact:
Dr. Patrick Amstutz, acting CEO
patrick.amstutz@molecularpartners.com
Tel: +41 (0) 44 755 77 00
Andreas.Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00
Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42
S.A. Noonan
Susan A. Noonan Communications, LLC
susan@sanoonan.com
Tel: +1 212 966 3650
Disclaimer
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.